Bioventus Inc (BVS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.81 is considered Undervalued compared with the five-year average of 22.40. The fair price of Bioventus Inc (BVS) is between 280.89 to 288.45 according to relative valuation method. Compared to the current price of 8.77 USD , Bioventus Inc By Undervalued By 96.88%.

Relative Value

Fair Zone

280.89-288.45

Current Price：8.77

96.88%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Bioventus Inc (BVS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Bioventus Inc (BVS) has a current Price-to-Book (P/B) ratio of 2.91. Compared to its 3-year average P/B ratio of 2.60, the current P/B ratio is approximately 11.97% higher. Relative to its 5-year average P/B ratio of 2.54, the current P/B ratio is about 14.61% higher. Bioventus Inc (BVS) has a Forward Free Cash Flow (FCF) yield of approximately 11.07%. Compared to its 3-year average FCF yield of 2.77%, the current FCF yield is approximately 299.61% lower. Relative to its 5-year average FCF yield of 1.67%, the current FCF yield is about 562.83% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BVS competitors is 111.49, providing a benchmark for relative valuation. Bioventus Inc Corp (BVS.O) exhibits a P/S ratio of 0.81, which is -99.27% above the industry average. Given its robust revenue growth of -0.23%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BVS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BVS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BVS currently overvalued or undervalued?

What is Bioventus Inc (BVS) fair value?

BVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Bioventus Inc (BVS) is between 280.89 to 288.45 according to relative valuation method.

How does BVS's valuation metrics compare to the industry average?

The average P/S ratio for BVS's competitors is 111.49, providing a benchmark for relative valuation. Bioventus Inc Corp (BVS) exhibits a P/S ratio of 0.81, which is -99.27% above the industry average. Given its robust revenue growth of -0.23%, this premium appears unsustainable.

What is the current P/B ratio for Bioventus Inc (BVS) as of Mar 02 2026?

As of Mar 02 2026, Bioventus Inc (BVS) has a P/B ratio of 2.91. This indicates that the market values BVS at 2.91 times its book value.

What is the current FCF Yield for Bioventus Inc (BVS) as of Mar 02 2026?

As of Mar 02 2026, Bioventus Inc (BVS) has a FCF Yield of 11.07%. This means that for every dollar of Bioventus Inc's market capitalization, the company generates 11.07 cents in free cash flow.

What is the current Forward P/E ratio for Bioventus Inc (BVS) as of Mar 02 2026?

As of Mar 02 2026, Bioventus Inc (BVS) has a Forward P/E ratio of 9.49. This means the market is willing to pay $9.49 for every dollar of Bioventus Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bioventus Inc (BVS) as of Mar 02 2026?

As of Mar 02 2026, Bioventus Inc (BVS) has a Forward P/S ratio of 0.81. This means the market is valuing BVS at $0.81 for every dollar of expected revenue over the next 12 months.

BVS Valuation